The role of GnRH metabolite, GnRH-(1-5), in endometrial cancer

Front Endocrinol (Lausanne). 2023 Apr 14:14:1183278. doi: 10.3389/fendo.2023.1183278. eCollection 2023.

Abstract

From the time of its discovery and isolation in the mammalian hypothalamus, the decapeptide, gonadotropin-releasing hormone (GnRH), has also been found to be expressed in non-hypothalamic tissues and can elicit a diverse array of functions both in the brain and periphery. In cancer, past studies have targeted the gonadotropin-releasing hormone receptors (GnRHR) as a way to treat reproductive cancers due to its anti-tumorigenic effects. On the contrary, its metabolite, GnRH-(1-5), behaves divergently from its parental peptide through putative orphan G-protein coupled receptor (oGPCR), GPR101. In this review, we will focus on the potential roles of GnRH-(1-5) in the periphery with an emphasis on its effects on endometrial cancer progression.

Keywords: EP24.15; GPR101; GnRH; GnRH-(1-5); endometrial cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Endometrial Neoplasms*
  • Female
  • Gonadotropin-Releasing Hormone* / metabolism
  • Humans
  • Peptide Fragments / metabolism
  • Receptors, LHRH / metabolism

Substances

  • Gonadotropin-Releasing Hormone
  • LHRH (1-5)
  • Peptide Fragments
  • Receptors, LHRH